Document is current
Any future updates will be listed below
-
Authors
Chandler, Francesca https://orcid.org/0000-0003-3465-7599
Reddy, Poli Adi Narayana
Bhutda, Smita
Ross, Rebecca L.
Datta, Arindam
Walden, Miriam
Walker, Kieran https://orcid.org/0000-0002-6694-2979
Di Donato, Stefano
Cassel, Joel A.
Prakesch, Michael A. https://orcid.org/0000-0003-2960-6471
Aman, Ahmed https://orcid.org/0000-0002-0275-205X
Datti, Alessandro https://orcid.org/0000-0001-6824-7382
Campbell, Lisa J.
Foglizzo, Martina https://orcid.org/0000-0001-9132-4737
Bell, Lillie https://orcid.org/0009-0001-9398-4031
Stein, Daniel N.
Ault, James R.
Al-awar, Rima S.
Calabrese, Antonio N. https://orcid.org/0000-0003-2437-7761
Sicheri, Frank https://orcid.org/0000-0002-9824-2117
Del Galdo, Francesco https://orcid.org/0000-0002-8528-2283
Salvino, Joseph M. https://orcid.org/0000-0002-2184-5980
Greenberg, Roger A. https://orcid.org/0000-0003-1326-8981
Zeqiraj, Elton https://orcid.org/0000-0003-0239-5926
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 13 February 2025
First Online: 17 March 2025
Competing interests
: E.Z., R.G., J.M.S. and F.S. are coinventors on a patent to use BRISC inhibitors as therapeutics (WO2024115713A1). J.M.S. owns equity in Alliance Discovery and the Barer Institute and consults for Syndeavor Therapeutics. The remaining authors declare no competing interests.
